Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy. 2012

Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

In Duchenne muscular dystrophy (DMD), dystrophin deficiency leading to progressive muscular degeneration is caused by frame-shifting mutations in the DMD gene. Antisense oligonucleotides (AONs) aim to restore the reading frame by skipping of a specific exon(s), thereby allowing the production of a shorter, but semifunctional protein, as is found in the mostly more mildly affected patients with Becker muscular dystrophy. AONs are currently being investigated in phase 3 placebo-controlled clinical trials. Most of the participating patients are treated symptomatically with corticosteroids (mainly predniso[lo]ne) to stabilize the muscle fibers, which might affect the uptake and/or efficiency of AONs. Therefore the effect of prednisolone on 2'-O-methyl phosphorothioate AON efficacy in patient-derived cultured muscle cells and the mdx mouse model (after local and systemic AON treatment) was assessed in this study. Both in vitro and in vivo skip efficiency and biomarker expression were comparable between saline- and prednisolone-cotreated cells and mice. After systemic exon 23-specific AON (23AON) treatment for 8 weeks, dystrophin was detectable in all treated mice. Western blot analyses indicated slightly higher dystrophin levels in prednisolone-treated mice, which might be explained by better muscle condition and consequently more target dystrophin pre-mRNA. In addition, fibrotic and regeneration biomarkers were normalized to some extent in prednisolone- and/or 23AON-treated mice. Overall these results show that the use of prednisone forms no barrier to participation in clinical trials with AONs.

UI MeSH Term Description Entries
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic
D016189 Dystrophin A muscle protein localized in surface membranes which is the product of the Duchenne/Becker muscular dystrophy gene. Individuals with Duchenne muscular dystrophy usually lack dystrophin completely while those with Becker muscular dystrophy have dystrophin of an altered size. It shares features with other cytoskeletal proteins such as SPECTRIN and alpha-actinin but the precise function of dystrophin is not clear. One possible role might be to preserve the integrity and alignment of the plasma membrane to the myofibrils during muscle contraction and relaxation. MW 400 kDa.
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018101 Mice, Inbred mdx A strain of mice arising from a spontaneous MUTATION (mdx) in inbred C57BL mice. This mutation is X chromosome-linked and produces viable homozygous animals that lack the muscle protein DYSTROPHIN, have high serum levels of muscle ENZYMES, and possess histological lesions similar to human MUSCULAR DYSTROPHY. The histological features, linkage, and map position of mdx make these mice a worthy animal model of DUCHENNE MUSCULAR DYSTROPHY. Mice, mdx,Mouse, Inbred mdx,Mouse, mdx,Inbred mdx Mice,Inbred mdx Mouse,mdx Mice,mdx Mouse

Related Publications

Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
March 2009, The journal of gene medicine,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
December 2019, Nucleic acid therapeutics,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
January 2011, Artificial DNA, PNA & XNA,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
September 2020, Gene therapy,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
September 2009, Annals of the New York Academy of Sciences,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
June 2012, Current gene therapy,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
March 2009, Human mutation,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
July 2007, BMC medical genetics,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
July 2021, JMA journal,
Ingrid E C Verhaart, and Hans Heemskerk, and Tatyana G Karnaoukh, and Ingrid G M Kolfschoten, and Anne Vroon, and Gert-Jan B van Ommen, and Judith C T van Deutekom, and Annemieke Aartsma-Rus
January 2021, Journal of neuromuscular diseases,
Copied contents to your clipboard!